Choline chloride receives fast track designation from FDA for intestinal failure associated liver disease

Fast track designation for this phospholipid substrate replacement therapy was granted based on data from a phase II RCT which found that in patients on parenteral nutrition, IV choline chloride resulted in a reversal of hepatic steatosis and an improvement in cholestasis.


Biospace Inc.